The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trial

Tebotelimab, a bispecific PD-1×LAG-3 DART molecule that blocks both PD-1 and LAG-3, was investigated for clinical safety and activity in a phase 1 dose-escalation and cohort-expansion clinical trial in patients with solid tumors or hematologic malignancies and disease progression on previous treatme...

Descripción completa

Detalles Bibliográficos
Autores principales: Luke, Jason J., Patel, Manish R., Blumenschein, George R., Hamilton, Erika, Chmielowski, Bartosz, Ulahannan, Susanna V., Connolly, Roisin M., Santa-Maria, Cesar A., Wang, Jie, Bahadur, Shakeela W., Weickhardt, Andrew, Asch, Adam S., Mallesara, Girish, Clingan, Philip, Dlugosz-Danecka, Monika, Tomaszewska-Kiecana, Monika, Pylypenko, Halyna, Hamad, Nada, Kindler, Hedy L., Sumrow, Bradley J., Kaminker, Patrick, Chen, Francine Z., Zhang, Xiaoyu, Shah, Kalpana, Smith, Douglas H., De Costa, Anushka, Li, Jonathan, Li, Hua, Sun, Jichao, Moore, Paul A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group US 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10667103/
https://www.ncbi.nlm.nih.gov/pubmed/37857711
http://dx.doi.org/10.1038/s41591-023-02593-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10667103/
https://www.ncbi.nlm.nih.gov/pubmed/37857711
http://dx.doi.org/10.1038/s41591-023-02593-0

Ejemplares similares